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COMPARATIVE ANALYSIS OF HYPOTHALAMIC DAMAGE CAUSED BY  
PEDIATRIC CRANIOPHARYNGIOMA VERSUS PEDIATRIC LOW GRADE  
GLIOMAS 
 
DAVID G. BARRETTO 
ABSTRACT 
 Numerous studies have suggested rapid weight gain following diagnosis and 
initial treatment of childhood craniopharyngioma (CP) due to the damage sustained by 
the hypothalamus. Hypothalamic lesions formed by the treatment of the tumor and/or by 
invasiveness of the tumor itself are known to cause intractable weight gain, known as 
hypothalamic obesity. In contrast, hypothalamic obesity manifested in pediatric low-
grade glioma (PLGG) patients is not as prominently addressed in literature; likely due to 
the expansive set of histological tumor subtypes that makes generalization challenging. 
Specifically, there is a lack of analysis that examines the difference in treatment, 
endocrinopathies, and weight gain between CP and PLGG patients.  
 The purpose of this study was to compare hypothalamic damage in subjects 
diagnosed with pediatric hypothalamic low-grade glioma versus subjects diagnosed with 
childhood craniopharyngioma. We hypothesized that CP patients will have a more rapid 
post diagnosis weight gain and a greater degree of obesity compared with PLGG patients 
due to the more invasive nature of the tumor and the aggressive surgical treatments 
involved.  
  v 
 We performed a retrospective review of the clinical records of patients who 
received a diagnosis of childhood craniopharyngioma or pediatric low-grade glioma at 
Dana-Farber Cancer Institute between 1980 and 2009. We identified 45 patients, who met 
criteria for evaluation, 28 were previously diagnosed with childhood craniopharyngioma 
and 17 were diagnosed with hypothalamic pediatric low-grade glioma. We analyzed the 
impact of treatment, the presence of endocrinopathies, and weight gain after diagnosis. 
We concluded that there was no statistically significant difference in the rate or 
magnitude of post diagnosis weight gain, disproving our initial hypotheses. 
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INTRODUCTION 
 
Hypothalamus 
 The hypothalamus is a brain structure that is located below the thalamus and part 
of the diencephalon that functions to regulate autonomic, endocrine, and behavioral 
mechanisms (1). As part of the diencephalon, the hypothalamus is a part of the forebrain, 
along with the thalamus, subthalamus, and epithalamus (5).  Anatomically, it makes up 
one percent of the total brain volume and has an approximate weight of 1 gram (6). The 
hypothalamus is the most ventral part of the diencephalon and lies along the walls of the 
third ventricle, just under the hypothalamic sulcus at its dorsal border, and continues 
along the floor of the ventricle (1-3). The ventral surface is exposed on the base of the 
brain and composed of three prominent features: the mammillary posterior region, the 
medial tuberal region that passes through the fornix, and the supraoptic anterior region 
that lies above the optic chiasm. It is the superior portion of the hypothalamus that 
borders the thalamus (2, 6).  
 The hypothalamus can be categorized anatomically into 3 generalized functional 
zones: the paraventricular, medial, and lateral (7). Neurons in the paraventricular zone 
behave functionally by controlling the release of pituitary hormones, regulating 
sympathetic nerve activity, and the control of food intake (8-10). Neurons of the medial 
zone are specialized to receive sensory information and establish adaptive behaviors (7). 
Lateral zone behaves as a relay station between the medial hypothalamus and 
cortical/limbic areas of the brain that control cognition and behavior. In addition, it acts 
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to relay signals to the somatic and autonomic systems that control stimulation associated 
with driven behaviors like food intake, sensorimotor coordination, and skeletal and 
autonomic motor functions (7, 11).  
 The main function of the hypothalamus is to maintain internal bodily homeostasis. 
This is carried out by a neuroendocrine function that utilizes the release and inhibition of 
eight key hormones from the anterior and posterior pituitary glands, respectively known 
as the adenohypophysis and neurohypophysis (6). In turn, hormones released by the 
hypophyses are used to regulate distal target organs and the peripheral hormones released 
by specific endocrine glands: the adrenal glands, thyroid gland, ovaries, and testes. The 
tropic hormones synthesized and released by the anterior pituitary are involved in the 
processes of endocrine and immune responses, metabolism, satiety regulation, 
cardiovascular regulation, sleep, stress, thermoregulation, and sexual behavior (3, 6). 
Hormones released by the posterior pituitary control water and electrolyte balance as well 
as uterine contraction during child birth and lactation in females (4). In turn, positive and 
negative feedback regulators send signals back to the hypothalamus, fine-tuning the 
activation and suppression of hormones released by the hypophyses and glands in order 
to preserve biological processes (6). 
 Adaptive responses by the hypothalamus to regulate body weight are 
accomplished by controlling appetite and satiety through the balance of 3 factors: food 
consumption, energy expenditure, and stored energy in the form of lipids. There are four 
main areas of the hypothalamus which control these three factors: the ventromedial 
nucleus of the hypothalamus (VMH), paraventricular nucleus (PVN), arcuate nucleus 
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(ARC), and the lateral hypothalamic area (LHA) (7, 12, 13). Distinct neuropeptides 
within these areas have positive and negative synergistic effects on appetite.  
 The PVN lies in the periventricular zone and secretes neuropeptides that have an 
indirect anorexigenic effect on food intake via absorption, digestion, response to stress, 
and the metabolism of fats. Neuropeptides in the PVN observed to produce anorexigenic 
responses include: corticotrophin-releasing hormone (CRH), thyrotropin-releasing 
hormone (TRH), and oxytocin (12, 13).  Secretion of oxytocin acts on the solitary tract 
nucleus in the medulla oblongata by modifying response to bordering satiety signals and 
inhibiting food intake (12). Secreted TRH regulate energy homeostasis and food intake 
through its influence on metabolic processes, thereby causing an anorexigenic response. 
These include increased lipolysis and fatty acid oxidation, an increase in core body 
temperature, modifications to the cephalic phase of digestion, and evidence of stress-
induced anorexia through interactions with the limbic nervous system (13, 17). Similarly, 
CRH promote stress-induced anorexia by activating the hypothalamic-pituitary-adrenal 
axis, causing the suppression of neural food-motivated responses in response to stress-
stimuli (14-16).   
 In the ARC, which lies in the periventricular zone, there are two distinct sets of 
neurons: one set of neurons that coexpress orexigenic responses via neuropeptide Y 
(NPY) and agouti-related protein (AgRP), and the other set of neurons that coexpress 
anorexigenic responses via pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-related transcript (CART) (7, 13). The α-melanocyte stimulating hormone 
(α-MSH) is produced by the precursor, POMC, which is post-transcriptionally altered and 
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released from the presynaptic terminals of POMC neurons. The α-MSH binds with high 
affinity to G protein-coupled receptors, melanocortin-3 and -4 receptor (MC3R, MC4R), 
activating catabolic processes that increase energy expenditure and reduce food intake 
(13, 18, 19).  Studies have shown that there is a down regulation of POMC expression 
during periods of negative energy balance (20, 21). NPY promotes food intake by 
increasing appetite ingestive behavior as a response to food stimuli (26). AgRP is 
released from neurons of ARC NPY- and AgRP- producing neurons and mediate their 
physiological effects on body weight by blocking G protein-coupled receptor signaling. 
AgRP competes with α-MSH to bind to MC3R and MC4R with high affinity, acting as a 
competitive antagonist (22, 23). AgRP also acts as an inverse agonist because binding 
causes a basal decrease in MC3R and MC4R signaling, which is not dependent on the 
concentration of agonists (24). CART is found to promote lipolysis, increasing energy 
expenditure, and increasing satiety as a result of afferent central vagal signals once food 
is sensed in the gut (25).  
 The LHA lies in the lateral zone and has extensive behavioral and autonomic 
output connections to the limbic system, brainstem, and spinal cord, which include 
specific functions controlling feeding behavior and energy balance. It contains two 
neuronal populations that produce orexigenic neuropeptides: orexins, also known as 
hypocretin, and melanin-concentrating hormone (MCH) (7, 12, 13). Orexins promote 
food intake by increasing arousal to food stimuli, strengthening the motivational and 
reward responses (12, 27). MCH has also been shown to have a significant role in 
stimulating motivational aspects of feeding. Previous studies illustrated knockout rats 
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lacking MCH or MCH receptor produced lean rats with an altered metabolism and a 
reduced operant response to high sugar or fat food stimuli, compared with control rats 
with the hormone present (12, 28, 29).      
 Located in the medial zone of the hypothalamus, the VMH is known to generate 
satiety and maintain glucose homeostasis. The VMH receives signals primarily from the 
ARC and contain neurons which produce brain-derived neutrophic factor (BDNF) (13). 
BDNF is a neuropeptide that stimulates an anorexigenic response that is sensitive to 
glucose levels and energy status (13, 30-32). Studies have shown that VMH neurons 
sensing an increase in glucose intake caused elevations in BDNF mRNA expressions 
(30). Conversely, extended fasting caused a decrease in BDNF expression, with elevation 
following refeeding (32). 
 Leptin is a cell signaling protein secreted by white adipose tissue, which plays a 
pivotal role in the regulation of food consumption and energy homeostasis. Serum 
concentrations of leptin signal body fat content to the hypothalamus via regions of the 
central nervous system (CNS), which regulate the main hypothalamic areas involved in 
energy homeostasis, primarily the ARC (33-35). Leptin is produced and secreted by 
white adipocytes, where the rate of leptin produced and the amount secreted is 
proportional to bodily adipose tissue mass, allowing the plasma leptin concentration to be 
used as a biomarker of adiposity (13, 34, 35).  
  During states of high body fat content, leptin produces a cascade, suppressing 
food intake and stimulating energy expenditure (13, 18, 33). Circulating leptin passes 
through the Blood Brain Barrier where it binds to ARC neuronal leptin receptors, causing 
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inhibition of neurons that express NPY and AgRP, while increasing mRNA levels of 
neurons that express POMC and CART, stimulating its release. Reducing NPY and 
AgRP potently decreases their food intake stimulation, thereby reducing appetite and 
ingestive behaviors to food stimuli (35, 36). Furthermore, increased CART stimulates 
increased lipid peroxidation, energy expenditure, and satiety signals as a result of afferent 
central vagal signals, amplifying central vagal signals sent to the brain by gut hormones 
like CCK (13, 25, 36) Increased POMC allows for increased α-MSH concentrations. 
With inhibition of AgRP as a competitive inhibitor, increased amounts of α-MSH is 
available to bind to MC3R and MC4R, causing a decrease in appetite and food intake, but 
also an increase in renal and lumbar sympathetic nerve activity (19, 35, 37). This 
increased sympathetic nerve activity promotes energy expenditure through fat oxidation, 
glycogenolysis, thermogenesis, and increased movement (47). 
 Conversely, reduced plasma leptin concentration, signifying low body fat content, 
promotes energy intake and limits energy expenditure. In the fasting state, the reduction 
of leptin concentration stimulates ARC neurons that express NPY and AgRP, and inhibit 
those that express POMC and CART. Increased NPY stimulates appetite and food 
ingesting behavior in response to food stimuli. Increased AgRP competitively inhibit the 
effects of α-MSH, causing increased food intake, decreased sympathetic nerve activity, 
and decreased energy expenditure (35, 36). Inhibition of POMC and CART further 
enhance these effects. Studies show that reduced leptin trigger the central nervous 
system’s adaptive responses to starvation in order to reduce energy expenditure of the 
immune system, fertility, growth, and metabolic rate (33). This includes the suppression 
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of sex hormones, growth hormone (GH), thyroxine (T4) and triiodothyronine (T3) levels, 
and lymphocyte proliferation and differentiation (33, 38, 39). Further studies show that 
detection thresholds are altered in response to food-related sensory input signals. These 
include the increased transcription of leptin receptors in olfactory mucosa as pre-
ingestive behavior, and the hyperpolarization of cells associated with taste behavioral 
responses to sweet compounds, making them less responsive to taste stimulation (40-43). 
 Insulin is another important adiposity signal with receptors in the ARC. It carries 
the same function as leptin, inhibiting the release of NPY and AgRP, while stimulating 
the release of POMC and CART (36, 57). Insulin concentrations in the cerebrospinal 
fluid are directly proportional to the level of concentration circulating in the plasma (36). 
Thus, during fasting states, the concentration of insulin is low, leading to the stimulation 
of the orexigenic pathway (NPY and AgRP) and the inhibition of the anorexigenic 
pathway (POMC and CART). This leads to increased feeding behavior and energy 
efficiency with reduced fat oxidation. During fed states, the concentration of insulin is 
high and the opposite takes place, resulting in decreased appetite and food intake, and 
increased sympathetic nerve activity leading to increased fat oxidation. (36, 47, 57).  
 In contrast to leptin and insulin, the stomach hormone, ghrelin, acts as an 
adiposity signal that produces opposing effects on the neurons of the ARC (47, 58). 
Ghrelin directly stimulates the neurons that express NPY and AgRP. Although Ghrelin 
doesn’t directly affect the mRNA levels of the neurons expressing POMC and CART, it 
indirectly inhibits these neurons through the release of an inhibitory neurotransmitter, 
GABA, secreted by NPY (59, 60). This triggers food seeking behavior with increased 
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energy efficiency, reducing the oxidation of fat in order to store more energy in states of 
fasting (47, 58). During fed states, the stomach secretes less ghrelin, which prevents NPY 
and AgRP neuronal activation and NPY neurotransmission, inhibiting food intake and 
decreasing appetite (47).   
 
Hypopituitarism and Hypothalamic Dysfunction 
 Due to their central midline position, the hypothalamus and the pituitary gland are 
susceptible to dysfunction via congenital abnormalities at the base of the skull or as 
secondary acquired dysfunction to pathological disease or treatment at the skull base (44-
46). Damage to the hypothalamus, pituitary, or the infundibulum that connects the two 
glands can cause hypopituitarism, defined as the impaired secretion of one or more 
pituitary hormones from the anterior and posterior pituitary (44, 46). Panhypopituitarism 
indicates the impaired secretion of all pituitary hormones, but is often used clinically to 
describe patients who are deficient in growth hormone, gonadotropins, and 
corticotrophins, while the posterior pituitary still retains function (50). Hypothalamic 
dysfunction and hypopituitarism can cause long term morbidity, including debilitating 
obesity disorders, fatigue, problems with temperature regulation, and disrupted circadian 
rhythms (44-46).   
 In most cases, acquired hypopituitarism manifests due to skull base mass lesions 
or their corresponding treatment of surgery or radiotherapy.  Brain tumors compress the 
pituitary stalk portal vessels due to its expansion in size or as a result to an increase in 
intrasellar pressure. Localized mass lesions causing hypopituitarism include gliomas, 
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craniopharyngiomas, arachnoid cysts, and Rathke cleft cysts (46). In patients with 
craniopharyngioma, 85 to 95 percent of patients suffer from endocrine deficits, with 80 to 
93 percent manifesting irreversible diabetes following complete resection of the tumor, 
and 75 percent manifesting growth hormone deficiencies (49).  
 Radiation-induced hypopituitarism is a common consequence of radiation therapy 
that occurs when the hypothalamic-pituitary axis lies within the field of administered 
radiation (45, 46, 51). For treatment of sellar and parasellar tumors, hypothalamic 
damage is considered to be present in the early pathophysiology of radiation-induced 
toxicity, which differs from the atrophy of the pituitary gland, which is considered a 
―late-onset contributing factor‖  (45, 51).  This occurs through the ionization of cell DNA 
that can lead to the degeneration of glial cells. Ionizing radiation may cause 
conformational changes in the DNA structure of the cell or lead to the destruction of the 
cell through the production of free radicals. The destruction of glial cells leads to neural 
demyelination and instability, causing neural damage in the hypothalamus-pituitary axis. 
Sub-acute damage involves vascular changes that may cause edema, or the accumulation 
of fluid. Chronic neural damage involves the vascular lining synthesizing more collagen 
and producing a thicker basement membrane, leading to the eradication of small blood 
vessels, necrosis of irradiated tissues, and atherogenesis, or the formation of plaques, in 
major brain arteries (51).  
 Anterior pituitary hormone deficits due to radiation treatments are more numerous 
and manifest at a greater rate as the radiation dose increases (46, 50, 51). Growth 
Hormone has been shown to be the most radiosensitive to the effects of radiation therapy 
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with doses as low as 18 Gy causing a deficiency (50, 51). Other anterior pituitary 
hormones, like Thyroid Stimulating Hormone (TSH), require greater radiation doses 
above 50 Gy to cause a deficiency (51).  
 Hypopituitarism has various effects depending on the age of onset, type of 
hormone that shows a deficit, and hormone replacement to normalize endocrine function. 
For instance, children who manifest GH deficiencies have a reduced growth velocity for 
their age, resulting in shorter stature and final height (51). Untreated GH deficient 
children attain an average final height of approximately 1 standard deviation below 
ethnically-, age-, and sex-matched controls (57). Adults face a greater risk of 
abnormalities in protein, fat, and carbohydrate metabolism, causing a decreased amount 
of lean body mass and higher fat mass. (50, 51). This results in muscle weakness, fatigue, 
and increased intra-abdominal or visceral fat deposition leading to central obesity. TSH is 
another pituitary hormone which carries a propensity towards central obesity as a 
consequence to its deficit. Patients manifest secondary hypothyroid symptoms, which 
include cold intolerance, weight gain, poor growth, delayed bone maturation, and fatigue 
(46, 50). Some of the symptoms caused by hormone deficits may be alleviated with 
hormone replacement therapy. For example, GH-deficient children who received 
adequately-dosed and timely GH replacements were shown on average to achieve a 
higher final height compared with those who were untreated or received a lower dose (51, 
53).  
 Hypothalamic dysfunction has a similar pathogenesis akin to hypopituitarism, 
where direct infiltration by skull base neoplasms, trauma, inflammatory disease, surgical 
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resection, or irradiation may inflict damage to the hypothalamus (46). The difference is, 
unlike hypopituitarism, many of the symptoms associated with hypothalamic dysfunction 
persist despite adequate hormone replacement therapy. Studies on craniopharyngioma 
patients who exhibited symptoms of fatigue and excessive daytime sleepiness were not 
alleviated by hormone replacements of cortisol nor thyroxine (for ACTH or TSH 
deficiency). Thus, patients are faced with long-term morbidities that include disrupted 
circadian rhythms and hypothalamic obesity (46, 47, 49).  
 Damage to the suprachiasmatic nucleus of the hypothalamus has been shown to 
cause sleep disturbances and daytime hypersomnolence. Evidence has been observed in 
craniopharyngioma patients that show the tumor, or the treatments associated, can create 
dysfunction in the hypothalamic circadian pacemaker, which controls the timing of the 
sleep propensity rhythm. In addition, there is a deficiency in melatonin secreted into the 
bloodstream by the pineal gland (52). It is believed that the dysfunctional circadian 
pacemaker causes disturbance in the mechanisms controlling daytime circadian arousal, 
leaving the sleep drive unopposed, thus causing the daytime hypersomnolence. Self-
reports of long term survivors of craniopharyngioma have shown persistent day time 
sleepiness, and difficulty falling asleep or staying asleep for the entire night (54). 
Hormone replacements of cortisol or thyroxine were shown to be ineffective at 
alleviating symptoms of daytime hypersomnolence, however there are self-reports of 
obese craniopharyngioma patients stating that there were some improvements with 
supplemental melatonin (55, 56).  
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 Dr. Joseph Babinski in 1900 and subsequently, Dr. Alfred Fröhlich in 1901 were 
one of the first to document medical case studies describing a link between hypothalamic 
damage and obesity. A major complication that manifests due to hypothalamic 
dysfunction is intractable weight gain, known as hypothalamic obesity, which is shown to 
persist regardless of caloric restriction (47, 48).  Hypothalamic obesity (HyOb) is caused 
by the impairment in hypothalamic regulatory centers controlling energy homeostasis, 
leading to significant polyphagia and weight gain (61, 62). Although, mechanisms of 
HyOb pathogenesis is not totally clear, known mechanisms include: the suppression of 
the sympathetic nervous system, resistance to insulin, and the loss of sensitivity to 
afferent peripheral humoral signals (47, 49, 61).  
 Damage to the some of the main areas of the hypothalamus that regulate energy 
homeostasis lead to HyOb. Previous studies show that destruction of the VMN, PVN, or 
ARC lead to the impairment of satiety signals (13, 49). Many of the neurons in these 
areas that normally produce anorexigenic neuropeptides in these areas are absent. These 
anorexigenic neuropeptides include: CRH, TRH, and Oxytocin in the PVN, POMC and 
CART in the ARC, and BDNF in the VMH (7, 12, 13). In addition, destruction of BDNF 
in the VMN causes hyperglycemia due to glucose levels no longer being monitored (13). 
In mice, injections of an inhibitor, colchicine, to each of the nuclei of the hypothalamus 
responsible for energy homeostasis, resulted in a substantial increase in fat mass, along 
with serum leptin and insensitivity to intracerebroventricular administration of leptin (63, 
64). 
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 Particularly, disruption of cortisol regulation by CRH and ACTH has been shown 
to lead to Hypothalamic Obesity. Surgical resection of craniopharyngioma in HyOb 
patients with ACTH deficiency caused a substantial elevation in the activity of 11 β-
hydroxysteroid dehydrogenase 1 (11β-HSD1), the enzyme that catalyzes the conversion 
to produce active cortisol (84, 85). Increased levels of 11β-HSD1-derived corticosterone 
in children have led to increased adiposity, with an associated increase in waist 
circumference and waist-to-hip ratio. In addition, there is a rise in body mass and 
resistance to insulin (85, 86).  
   The death or absence of VMH neurons prevents the integration of afferent leptin 
signaling. Patients who manifested HyOb after surgical resection of craniopharyngioma 
were found to have remarkably higher levels of leptin for their body mass index (BMI), 
indicating a manifested leptin resistance (66). Further studies involving mice with 
hypothalamic lesions showed a 20-fold increase in the level of leptin mRNA in the 
adipose tissue. This hyperleptinaemia confirms the unresponsiveness of hypothalamic 
leptin receptors (61, 65).  Disrupted leptin signaling leads to deregulation of adipocyte 
levels in the body, decreased metabolic rate, and increased food intake (33-35). 
 There is also evidence that HyOb causes decreased ghrelin suppression. A study 
involving 15 subjects with HyOb showed dampened and delayed ghrelin suppression 
when compared with 15 obese BMI-matched controls (67). This suggests an increase in 
ghrelin exposure, which may further contribute to the intractable weight gain, although 
further studies are needed to confirm this hypothesis. 
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  Another mechanism of the HyOb pathogenesis is the suppression of the 
sympathetic nervous system due to unilateral denervation to white adipose tissue, causing 
impaired lipid mobilization and decreased sympathetic tone (61, 68). This is documented 
by patients exhibiting an impaired ability to generate an epinephrine response to insulin-
induced hypoglycemia, lowered 24-hour epinephrine secretion, and lowered morning 
heart rates (47, 69, 71). There is also evidence of HyOb patients having a decreased basal 
metabolic rate. The oxidation rate of glycerol-3-phosphate by the mitochondria of 
adipose tissue was reduced, indicating a reduction in the rate of metabolism of adipose 
tissue, (61, 70).  
 Insulin hypersecretion is another symptom of Hypothalamic Obesity, defined by 
insulin resistance. Fasting insulin and insulin secreted after given a 75g oral glucose 
tolerance test were remarkably high in HyOb patients, with measured levels of fasting 
insulin being greater than weight-matched controls (70, 72). This hyperinsulinaemia was 
shown to be present in craniopharyngioma patients immediately following surgical 
resection treatment, prior to the onset of obesity, suggesting direct hypothalamic 
regulation of insulin release by beta cells of the pancreas (73). 
  Three mechanisms are attributed to the insulin hypersecretion: loss of POMC 
neurons, loss of central insulin signaling, and an increase in vagal stimulation (74-76). 
Insulin is directly regulated by α-MSH, thus loss of POMC neurons cause loss of insulin 
suppression, severely increasing insulin levels (75). Previous studies on knockout mice 
lacking neuronal insulin receptors show an elevation in peripheral insulin, food intake, 
and insulin resistance indicating signaling of insulin in the brain as a regulator of 
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peripheral plasma insulin levels (76). Another mechanism of HyOb hyperinsulinaemia is 
the increased stimulation of the parasympathetic nervous system due to loss of inhibition. 
Previous studies have shown that a subdiaphragmatic vagotomy, inhibiting vagal 
stimulation, on adult female HyOb rats prevented obesity, hyperinsulinaemia, and 
proliferation of pancreatic beta cells. However, it did not prevent from overeating (77-
79). 
 Hypothalamic Obesity imposes the risk of developing further health 
complications, particularly those associated with Metabolic Syndrome. Metabolic 
Syndrome is defined by a number of adverse health outcomes: elevated blood pressure, 
insulin resistance with or without glucose intolerance, abdominal obesity, atherogenic 
dyslipidemia, leading to an increased risk of cardiovascular disease, stroke, and coronary 
heart disease (80, 81, 83). Atherogenic dyslipidemia pertains to an increase in 
triglycerides and low-density lipoprotein (LDL) cholesterol levels, with decreased levels 
of high-density lipoproteins (HDLs). Atherogenic dyslipidemia is directly associated with 
an increased risk of myocardial infarctions (82). Obesity may cause inflammation due to 
excess adipose tissue releasing inflammatory cytokines. This promotes the production 
and release of the clotting factor, fibrinogen, forming fibrin clots in the blood. This 
proinflammation and prothrombotic state is associated with an increased risk of 
cardiovascular disease (80, 83). 
 Management of HyOb morbidities remains suboptimal due to the numerous facets 
of the disorder, calling for further research on therapeutic drug protocols to improve the 
quality of life of HyOb patients. Rosenbaum et al. have conducted experiments restricting 
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caloric intake in obese patients to reduce weight by 10 percent in order to induce a 
starvation state, while exogenously administering leptin in dosing that reflected pre-
starvation physiological levels. The result was a generated response to the administered 
leptin, with energy expenditure, skeletal muscle work efficiency, sympathetic nervous 
system tone, appetite control, and thyroid hormone concentrations returning to pre-weight 
loss levels (87, 88). This marks evidence of leptin sensitivity being improved through 
forced weight loss.  
 Another area of treatment for HyOb patients is through the activation of the 
sympathetic nervous system. There is evidence of ephedrine stimulating β-adrenergic 
receptors of the sympathetic nervous system, causing an increase in energy expenditure 
with a decrease in food intake (90). In a case study in 2008, administering caffeine (200 
mg) and ephedrine hydrochloride (25 mg), to 3 HyOb patients that were gaining weight 
at initial assessment, acted to prevent further weight gain and maintained a significant 
weight loss in 2 of the 3 patients. It was believed that these ―sympathomimetic drugs‖ 
were acting peripherally to increase sympathetic tone and metabolism (89).     
 Insulin hypersecretion may be suppressed with the use of somatostatins. 
Suppression of insulin secretion promoted a decrease in fatigue, hunger, and body 
weight. A double blind placebo-controlled study was conducted on 18 pediatric HyOb 
patients testing the effects of a particular somatostatin drug, octreotide. Results showed 
stabilization in weight and BMI, suppression in insulin, and improved quality of life, 
which was correlated with the amount of octreotide dose given (91).  
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 An alternative to drug therapy to treat symptoms of hypothalamic obesity is 
gastric bypass surgery.  Initial reports of bariatric surgery performed on 
craniopharyngioma patients with hypothalamic obesity seem promising, showing BMI 
decreasing or being stabilized in the years following surgery, along with an improved 
feeding behavior response. However, the scope of the studies have been limited, and long 
term follow-up studies on the safety and efficacy of bariatric surgery have yet to be 
examined.  
 Together, hypothalamic dysfunction and hypopituitarism causes intractable 
obesity, known as hypothalamic obesity, through impaired sensitivity to feeding signals 
in the hypothalamus, reduction in metabolic rate, and hypersomnolence. It is necessary to 
examine two types of invasive brain tumors that are known to affect the hypothalamus: 
Childhood craniopharyngiomas (CPs) and pediatric low-grade gliomas (PLGGs). 
 
Childhood Craniopharyngiomas and Pediatric Low-Grade Gliomas 
 Craniopharyngiomas are rare, benign, epithelial tumors that arise from ectoblastic 
remnants of Rathke’s pouch, and can be found anywhere along the path of the 
craniopharyngeal duct. They are usually found in the sellar/parasellar area in the 
hypothalamic and pituitary regions of the brain (94, 95). CPs are the most common 
intracranial tumors of nonglial origin in the pediatric population, with a high survival rate 
of approximately 92 percent. However, because of its tendency to infiltrate the 
hypothalamus, patients tend to experience significant morbidity, and in some cases 
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mortality more than 10 years after diagnosis, due to sequelae caused by hypothalamic 
obesity (49, 95). 
 Craniopharyngiomas are classified by the World Health Organization as a grade I 
tumor, which is considered to be histologically benign (92). They are classified 
histologically into two variants: an adamantinomatous subtype, normally found in 
childhood onset craniopharyngiomas, and squamous-papillary subtype, normally found in 
adults. Mixed forms of the two subtypes can also exist (92, 93, 94). Approximately 96 
percent of childhood craniopharyngioma cases are of the adamantinomatous subtype 
versus up to 2 percent being of the squamous-papillary subtype (94, 96). The histology of 
the adamantinomatous subtype differs from the papillary by forming a more indistinct, 
and adherent interface with the surrounding brain tissue and vascular structures. In 
contrast, the papillary subtype is more circumscribed and infiltrates adjacent brain tissue 
less frequently (94, 96). 
    Incidence rates of CPs are very low with an overall incidence of 0.5 to 2.0 cases 
per million people each year (49). Craniopharyngiomas are the most common lesions to 
involve the hypothalamic-pituitary axis in children, accounting for 2 to 5 percent of all 
intracranial neoplasms, and 5.6 to 15 percent of intracranial tumors in children (94, 97). 
Peak incidence rates of CP occur at the age of 5 to 14 years, although it can be detected at 
any age, including pre- and neonatal periods (97).   
 Clinical manifestations initially presented at diagnosis are predominantly 
headaches, nausea and vomiting, and visual impairment. Other less common presenting 
symptoms include impaired motor functions, seizures, and psychiatric symptoms (49). 
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There are also endocrine deficits which, studies show, manifest at a time point far before 
initial diagnosis of CP is made. Many of the CP patients had a history of weight gain, 
reduced growth rate at the time of diagnosis, and one to three hormone deficits (95, 98). 
It has been postulated that particular clinical manifestations are based upon the age group 
of the patient. There are indications where the most commonly presented symptoms of 
increased intracranial pressure are reported in young children, sexual immaturity are 
reported in adolescents, and visual impairments are reported in young adults (99). The 
objectives of treatment are to relieve these clinical manifestations and to prevent further 
tumor progression and regrowth. 
 The primary therapeutic modality most widely used for CP is surgery and 
radiation, with attention to the preservation of visual and hypothalamic function. To 
prevent recurrence of disease, the preferred option is complete removal of the tumor by 
surgical resection, known as gross total resection (GTR) (49, 101, 102). For tumors with 
extensive hypothalamic involvement, GTR is not recommended due to the increased risk 
of hypothalamic damage. Rather, a partial removal (PR) or subtotal resection of the 
tumor is preferred followed by adjuvant external beam irradiation. Studies show that in 
cases with subtotal resection alone, chance of progression of the residual tumor is 71 to 
90 percent. In contrast, PR followed by radiotherapy decreases the chance of progression 
to 21 percent (100, 102). Thus, radiation has been shown to prevent progression of the 
tumor, which is why it is utilized following subtotal resection for tumors extending into 
the hypothalamus.   
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 Unfortunately, hypothalamic damage is a common, inevitable consequence of CP, 
regardless of the modality of treatment. An examination of the MRI’s of 63 CP survivors 
indicated that excessive post-operative obesity primarily occurs in patients who have 
sustained ―severe, bilateral hypothalamic damage‖. All of the subjects who were severely 
obese after surgery showed evidence of an impaired hypothalamus, with either a 
completely deficient or an extensively damaged third ventricle floor (106). Hypothalamic 
obesity is the most common manifestation of hypothalamic damage, reported in 
approximately 40 to 60 percent of CP patients treated surgically in conjunction with or 
without radiation (66, 94). This results, as previously mentioned, from the disruption of 
signaling to mechanisms of the hypothalamus that control energy homeostasis, satiety, 
and hunger, leading to reduced physical activity, leptin and ghrelin insensitivity, vagally 
induced insulin hypersecretion, and hypersomnolence.  
 CP increases the prevalence of risk factors for developing atherosclerotic 
cardiovascular disease (103). Adult subjects with childhood onset craniopharyngioma 
exhibited increased serum levels of high-sensitivity C-reactive protein (hs-CRP) and LDL 
concentrations, indicating a greater percent of subjects (48%) having at least a 1.7 times 
greater increased risk of cardiovascular disease compared with matched controls (29%). 
In addition, the ratio of the lipid-transporting proteins, apolipoprotein B (ApoB) to 
apolipoprotein A1 (ApoA-I), was calculated to determine if there is an increased risk of 
myocardial infarction. Elevated cardiovascular disease risk was identified in 52 percent 
of patients compared with 33 percent in matched controls. Conventional hormone 
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replacement was insufficient to normalize cardiovascular disease risk, suggesting 
implications for irreversible hypothalamic damage (103-105). 
 Patients who presented with a high BMI at the time of diagnosis were at higher 
risk for developing hypothalamic obesity. Analysis on preoperative risk factors for 
postoperative obesity found that CP with hypothalamic involvement caused a mean 
increase in BMI compared with patients lacking hypothalamic involvement. In addition, 
endocrine deficiencies and hormonal substitution therapy did not seem to have a 
significant impact on the development of HyOb in CP patients (95). Other studies have 
shown that the degree of obesity is positively correlated with the degree and extent of 
hypothalamic damage, usually from surgical resection and/or irradiation (100).  
 Pediatric low-grade gliomas encompass a diverse set of uncommon, slow 
growing, neoplasms, which are estimated to account for 30 to 50 percent of pediatric 
CNS tumors. These tumors typically involve midline structures of the brain, like the 
cerebellum, brainstem, hypothalamus, and optic pathway (107, 108). Like CP patients, 
PLGG patients have a high survival rate, with a 5-year overall survival at 94.6 to 97 
percent and a 15-year overall survival at 86 percent (107, 109, 110).  
 Low-grade gliomas are neuroectodermal tumors that originate from glial cells of 
the CNS that include oligodendrocytes and astrocytes. Three types of tumors are pure 
astrocytomas, pure oligodendrogliomas, or mixed glioneuronal tumors. Tumor subtypes 
are classified by the World Health Organization as Grade I and Grade II with the majority 
of PLGGs being histologically benign, and not undergoing malignant transformation. 
Grading is based on a number of histological factors that include: presence of necrosis, 
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giant cells, mitosis, proliferation, hyperchromatic nuclei, and pleomorphic cells. By 
definition, Grade I tumors have well circumscribed borders, while Grade II are ―diffusely 
infiltrating with bizarre nuclei‖ (92, 108, 110).  
 PLGGs are difficult to categorize because they can occur anywhere in the CNS 
and comprise of multiple different tumor histologies. The most common location is the 
cerebellum, where cerebellar PLGGs make up approximately 15 to 25 percent of all 
pediatric CNS tumors, followed by gliomas in the cerebrum at 10 to 15 percent, gliomas 
of the midline structures, which account for hypothalamic gliomas, at 10 to 15 percent, 
optic pathway gliomas at 5 percent, and brain stem gliomas at 2 to 4 percent (108, 109). 
Neurofibromatosis type 1 (NF1), a benign soft tissue tumor, has been known to develop 
into 70% of the optic pathway gliomas and hypothalamic gliomas. Nearly a fifth of 
children diagnosed with NF1 will develop into an optic pathway or hypothalamic glioma 
(108). 
 The therapeutic modalities for pediatric low-grade gliomas are frequently less 
invasive than the procedures to treat childhood craniopharyngioma. Other than optic 
pathway/hypothalamic gliomas, the initial management of PLGGs is surgery. Gross total 
resection is considered the most consistent prognostic factor for progression-free overall 
survival, with associated 10-year overall survival rate of 90% with a low chance of 
recurrence (107, 109, 112). If a subtotal resection is performed, usually adjuvant therapy 
does not take place unless there are signs of tumor progression. Chemotherapy is 
considered the primary postoperative adjuvant therapy for progressive PLGGs versus 
irradiation, which have little evidence suggesting improved overall survival. In contrast, 
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optic pathway gliomas and hypothalamic gliomas do not utilize surgery or radiation as 
initial therapeutic measures. Surgical resection and irradiation therapy is typically 
avoided due to an increased risk of developing a stroke and endocrine dysfunction, 
including obesity and hypopituitarism. Therefore, chemotherapy is used as initial therapy 
for optic pathway/hypothalamic gliomas to preserve hypothalamic function and attain the 
best chances of progression-free survival (108, 113, 114).   
 PLGG survivors face long-term endocrinopathies based on tumor location and the 
extent of surgical resection. In a study examining long-term morbidities in PLGG 
patients, increases in cumulative incidence rates of obesity, hormone deficiencies, and 
insulin resistance were associated with tumor location in the diencephalon (107, 125). 
This is observed in posterior optic nerve gliomas, which tend to grow into larger masses 
that compress the hypothalamus or obstruct the anterior third ventricle, impinging on 
normal hypothalamic signaling and causing hypothalamic dysfunction (111).  
 Subtotal resections of tumors tend to cause tumor progression with decreased 
long-term overall survival rates. PLGG subjects with at least 90 percent of their tumor 
resected had an overall survival rate of 91 percent at 8-years post-diagnosis. In contrast, 
patients with partially resected tumors had an overall survival rate of only 60 percent 
(110).  Out of all unresected/partially resected PLGG tumors, hypothalamic/chiasmatic 
gliomas carry the most sustained risk for tumor progression, which significantly increases 
the risk of long term morbidities. In a study examining long term PLGG survivors with 
progressive hypothalamic/chiasmatic gliomas, 75 percent were found to be 
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obese/overweight, more than half were GH deficient, ACTH deficient, and hypothyroid, 
and nearly 25 percent had insulin resistance (107).     
 In contrast to childhood craniopharyngiomas inducing hypothalamic obesity, 
pediatric low-grade gliomas are known to induce intractable weight loss, related to 
hypothalamic dysfunction, known as Diencephalic Syndrome (DS). DS is a rare, 
potentially lethal, multifaceted condition, marked with causing a failure to thrive in 
infants and young adults. DS patients are defined by the absence of subcutaneous adipose 
tissue, in spite of a normal or slightly diminished caloric intake, while maintaining an 
age-appropriate linear growth rate. Initial reports in 1951 described clinical 
characteristics of severe emaciation, hyper alertness, increased vigor and/or hyperkinesia, 
irritability, pallor, and normal or accelerated linear growth. Other symptoms that may be 
associated with DS include: involuntary eye movements (nystagmus), optic atrophy, and 
increased intracranial pressure (115-117).  
 Diencephalic Syndrome is described being almost exclusively associated with 
lesions of the hypothalamic-optic chiasm, being predominantly found in patients with 
juvenile pilocytic astocytomas (116). In the first year of life, DS has been reported in 5 
percent of intracranial tumors, 15 percent of optic pathway tumors, and 21 percent of 
hypothalamic glioma tumors (119-121). Although the general frequency of dissemination 
of low-grade gliomas is approximately 5 percent, it has been suggested that there is an 
association between DS and early dissemination of PLGGs. Therefore, despite being 
histologically low-grade, the tumors of DS patients are often aggressive in behavior (116, 
117).        
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 DS has a significant impact on the hypothalamic-pituitary axis, which has an 
effect on the mechanisms that modulate energy expenditure, appetite, and rate of growth. 
Vlachopapadopoulou et al found that total energy expenditure for DS patients was found 
to be 30 to 50 percent higher than matched controls and 13 percent higher than the 
patient’s energy intake. This suggests that weight loss and emaciation is due to an 
excessive expenditure of energy (122). Although the specific mechanism of cachexia 
manifestation in PLGG patients is unknown, it is believed to be directly attributed to the 
LGG tumor itself. It has been postulated that the LGG tumor produces an excess of a 
lipolytic peptide, β-lipotropin, which is a fat mobilizing protein. This may account for the 
loss of subcutaneous adipose tissue and partial GH resistance. A decrease in tumor size 
following therapy was also followed by a rapid weight gain (123, 124).  
 Several reports confirm an elevation in basal GH concentrations, partial GH 
suppression after administration of a glucose load, and normal Insulin-like growth factor 
1 (IGF-1) in DS patients before undergoing treatment of the tumor, which many studies 
suggest to be indicative of an acquired partial GH resistance. Elevated cortisol levels may 
contribute to the stimulation of GH secretion. Furthermore, some patients had ghrelin 
concentrations, before treatment, that were more than twice the level of normal weight 
controls, which may stimulate GH release (117, 118, 123).  
 According to previous studies, leptin regulation does not seem to be altered in DS 
patients; however, there are new implications that suggest otherwise. Brauner et al 
reports of measured plasma leptin concentrations in DS patients correlating with their 
BMI before and after treatment. Concentrations were similar to leptin levels in BMI-
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matched controls (118). They hypothesized that this suggests the regulation of leptin is 
not altered. However, a new case report examined a patient with measured leptin 
concentrations that fell following weight gain in response to treatment that decreased 
tumor size. They attributed this paradoxical response as either leptin axis dysregulation in 
DS or the PLGG diencephalic tumor impacting leptin secretion (126).  
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SPECIFIC AIMS 
 
 The purpose of this study was to compare hypothalamic damage in subjects 
diagnosed with pediatric hypothalamic low-grade glioma versus subjects diagnosed with 
childhood craniopharyngioma. Numerous studies have suggested rapid weight gain 
following diagnosis and initial treatment of CP due to the damage sustained by the 
hypothalamus. Hypothalamic lesions formed by surgery/irradiation therapy, or by 
invasiveness of the tumor itself, are known to cause intractable weight gain. In contrast, 
hypothalamic obesity manifested in PLGGs is not as prominently addressed in literature; 
likely due to the expansive set of histological tumor subtypes that makes generalization 
challenging. Specifically, there is a lack of in-depth literature that examines the 
difference of treatment, endocrinopathies, and weight gain post diagnosis between CP 
versus PLGGs.  PLGGs appear to have less of an impact on hypothalamic obesity and are 
even related, in some rare cases, to directly produce emaciation and intractable weight 
loss. We hypothesized that CP patients will have a more rapid post diagnosis weight gain 
and a greater degree of obesity compared with PLGG patients. This study was 
implemented to investigate whether a difference existed in post diagnosis weight gain of 
CP and PLGG patients. 
 This study utilized data from the brain tumor database at Dana-Farber Cancer 
Institute to examine the extent of obesity of pediatric low-grade glioma patients versus 
childhood craniopharyngioma patients at 6 months post-diagnosis, 5 years post-diagnosis, 
and at their most recent visit. Statistical analysis was performed to evaluate if a statistical 
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difference exists in post diagnosis BMI between diseases. Additional analyses were 
performed to identify endocrine dysfunctions that are present, the frontline treatments 
received, and the impact of treatment administered on the degree of obesity.  
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METHODS 
 
 
Patient Population 
 We performed a retrospective review of the clinical records of patients who 
received a diagnosis of childhood craniopharyngioma or pediatric low-grade glioma at 
Dana-Farber Cancer Institute between 1980 and 2009. The brain tumor database includes 
over 900 patients. The Dana-Farber Cancer Institute Institutional Review Board approved 
data collection efforts for use in this study. Patients were included in the study if they met 
the following inclusion criteria: being younger than 18 years old at the date of diagnosis, 
having been evaluated for care at Dana-Farber Cancer Institute, receiving a biopsy-
proven diagnosis of craniopharyngioma or a brain tumor classified as a low-grade 
glioma. Patients were excluded from the study if they met any of the following criteria: 
being lost to follow-up after initial diagnosis, at Dana-Faber Cancer Institute, and/or 
being over the age of 18 at the time of diagnosis. Patients seen for a second opinion but 
not followed primarily at Dana Farber Cancer Institute were also excluded. 
 Hypothalamic PLGGs were diagnosed by histopathologic confirmation of a grade 
1 (pilocytic) astrocytoma or grade 2 astrocytoma. A grade 2 astrocytoma include: 
fibrillary astrocytoma, pilomyxoid, oligoastrocytoma, oligodendroglioma, or low-grade 
astrocytic growths not otherwise specified. Optic pathway tumors acknowledged to be a 
glioma by neuroimaging, but without biopsy as evidence, were included in the study.     
  We were able to identify 45 patients (30 males and 15 females) who fit the 
criteria for inclusion in the study. Of the 45 patients, 28 were previously diagnosed with 
 30 
childhood craniopharyngioma and 17 were diagnosed with pediatric low-grade glioma. 
Details on age, sex, height, weight, frontline treatments, extent of resection, and 
cumulative radiation dose were extracted from patient medical records.  Height and 
weight were acquired from patient health records to calculate the body mass index (BMI), 
used as a measure of obesity. BMI was calculated using the formula, [BMI = weight 
(kilograms) ÷ height
2
 (square meters)]. Height and weight data were collected for each 
patient at the date of their cancer diagnosis, 6 months after diagnosis, 5 years after 
diagnosis, and at their latest follow-up visit. 
  
Statistical Analyses  
 Statistical analysis was performed by our informatics team of the pediatric 
oncology department at Dana-Farber Cancer Institute using SPSS software. 
 To compare the weight status of pediatric patients, BMI standard deviation scores, 
also known as BMI z-scores, were used as a measure of relative weight, adjusted for 
child age and sex (Table 1).  BMI z-scores were assigned to patients from age 2 to 20 
years old, and are based on body mass index-for-age growth charts obtained from the 
Center for Disease Control website for reference (www.cdc.gov/growthcharts).  Z-scores 
for infants less than 2 years old were based on age, sex, and weight, rather than BMI. The 
degree of obesity was based off of BMI reference standards produced by the International 
Obesity Task Force (IOTF). 
 Patients of ages 0 to 23.9 months were assigned a z-score based on weight. 
Patients age 24 months to 239.9 months were assigned a z-score based on BMI. For 
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patients age 0 to 239.9 months, the degree of obesity was based on z-score, with z less 
than -1 assigned as being ―underweight‖, equal to or greater than -1 but less than 1 being 
―normal‖, equal to or greater than 1.5 but less than 2 being ―obese‖, and greater than or 
equal to 2 being ―morbidly obese‖. For patients age 20 years old or greater, the degree of 
obesity was based on the BMI: less than 18.5 being ―underweight‖, greater than or equal 
to 18.5 but less than 25 being ―normal‖, greater than or equal to 25 but less than 30 being 
―overweight‖, greater than or equal to 30 but less than 40 being ―obese‖, and greater than 
or equal to 40 being considered ―morbidly obese‖. 
 
Table 1. Degree of Obesity with Corresponding BMI/BMI Z-Scores  
 
 
 A Wilcoxon rank sum test is a non-parametric statistical hypothesis test that 
assesses whether the sum of ranks differ between two sample cohorts. A two-sided 
Wilcoxon test was used to compare the BMI of CP versus PLGG patients at 6 months 
post diagnosis, 5 years post diagnosis, and the overall change in BMI from diagnosis until 
the last date of contact.  
Degree of obesity Age < 2 years old Age 2 - 20 years old Age > 20 years old 
Underweight Z < -1 Z < -1 BMI < 18.5 
Normal -1 ≤ Z < 1 -1 ≤ Z < 1 18.5 ≤ BMI < 25 
Overweight 1 ≤ Z < 1.5 1 ≤ Z < 1.5 25 ≤ BMI < 30 
Obese 1.5 ≤ Z < 2 1.5 ≤ Z < 2 30 ≤ BMI < 40 
Morbidly obese Z ≥ 2 Z ≥ 2 BMI ≥ 40 
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   The frontline treatments received by the proportion of patients were 
summarized. Results were categorized by disease type. The variables of this analysis 
included having: surgery alone, radiation therapy (XRT) alone, chemotherapy alone, 
surgery + XRT, surgery + chemotherapy, XRT + chemotherapy, or surgery + XRT + 
chemotherapy.  
 The proportion of patients was calculated, overall and by each tumor type, in 
terms of: the presence of endocrinopathies, whether the tumor impedes on the anterior or 
posterior pituitary, hormonal deficiencies, and the presence of diabetes insipidus. For 
each proportion, a 95% confidence interval was calculated. A Fisher’s exact test was 
utilized to compare the proportions between the two tumor types. Tumor location was 
determined based on which particular hormones were deficient.    
 The extent of treatment administered was compared with the degree of obesity 
overall by utilizing a two-sided Wilcoxen test. We explored the degree of obesity in 
patients who received a gross total resection versus subtotal as frontline treatment. In 
addition, we examined the impact of cumulative radiation dose administered to all 
patients on the degree of obesity. Results were depicted graphically on a boxplot.  
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RESULTS 
 
 
 There was not a significant difference in BMIs and the rate of weight gain 
between low-grade glioma patients and craniopharyngioma patients 6 months after 
diagnosis, 5 years after diagnosis, and at their most recent visit. P-values and data are 
summarized in Table 2.  
Table 2. Comparison of CP and LGG Patient BMI Over time 
*two-sided p-values of Wilcoxon tests 
 
 Proportions of each frontline treatment and combinations of the treatments 
received by the patients are summarized in Table 3. Out of the 28 craniopharyngioma 
patients, 14 (50%) underwent surgery alone, while the other 14 (50%) had a subtotal 
resection and radiation therapy. Similarly, 8 (48%) received radiation treatment either by 
itself or in combination with surgery and/or chemotherapy Only 3 (18%) out of the 17 
 Diagnosis N Mean p-value* 
BMI at 6 months post diagnosis Low-grade glioma 
 
14 22.5 0.3 
Craniopharyngioma 
 
21 23.6 
BMI at 5 years post diagnosis Low-grade glioma 
 
14 30.4 0.9 
Craniopharyngioma 
 
26 29.0 
Change in BMI from diagnosis until most 
recent visit 
Low-grade glioma 
 
15 10.0 0.1 
Craniopharyngioma 
 
26 16.1 
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PLGG patients had a gross total resection as primary treatment. 8 (48%) out of the 17 
PLGG patients had a subtotal resection with either radiation, chemotherapy, or a 
combination of the two.   
Table 3. Proportions of Frontline Treatments and Combinations of Treatments 
Received 
 Overall 
N=45  
N(%) 
Craniopharyngioma 
N=28 
N(%) 
Low-grade glioma 
N=17 
N(%) 
None 1(2%) 0 1(6%) 
Surgery Alone 17(38%) 14(50%) 3(18%) 
Surgery + XRT 17(38%) 14(50%) 3(18%) 
Surgery + Chemotherapy 4(9%) 0 4(24%) 
XRT Alone 3(7%) 0 3(18%) 
XRT + Chemotherapy 1(2%) 0 1(6%) 
Chemotherapy Alone 1(2%) 0 1(6%) 
Surgery + XRT+ Chemotherapy 1(2%) 0 1(6%) 
XRT = Radiation Therapy  
  
 The proportions of patients in each disease outcomes are summarized in Table 4. 
Endocrinopathies were found to be manifested in 27/28 (96% with 95% confidence 
interval between 90-100%) of CP patients and 13/17 (76% with 95% confidence interval 
between 56-97%) of PLGG patients. Out of the 45 total patients, 40 have tumors that 
impede the anterior pituitary and 30 have tumors that impede the posterior pituitary. 
There was found to be no statistically significant difference in the presence of 
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endocrinopathies between CP and PLGG patients. However, there is a statistically 
significant difference in adrenal insufficiency (p = 0.03), being in 17/28 (61% with 95% 
confidence interval between 43-79%) of CP patients compared to 4/17 (24% with 95% 
confidence interval between 3-44%).  
 
Table 4. Proportions of Selected Disease Outcomes 
*Two-sided p-value of Fisher’s exact test to compare the proportions between two 
disease groups. 
**There are overlaps in tumor locations 
  
 Wilcoxon tests were performed to compare the BMI at different time points for 
each type of treatment administered. Data and p-values are summarized in Tables 5-7. 
There was no statistically significant difference in BMI between CP and PLGG who had 
surgery and PLGG patients who did not have surgery (Table 5). Furthermore, there was 
no statistically significant difference in BMI in patients that have undergone gross total 
resection versus those who had a subtotal resection. 
 Overall 
N=45  
N(%, 95% CI) 
Craniopharyngioma 
N=28 
N(%, 95% CI) 
Low-grade glioma 
N=17 
N(%, 95% CI) 
p-
value* 
Endocrinopathies 
(present) 
40(89%, 80%-98%) 27(96%, 90%-100%) 13(76%, 56%-97%) 0.06 
Tumor 
Location 
Anterior 40 24 16 NA** 
Posterior 30 24 6 
Hypothyroidism 27(60%, 46%-74%) 18(64%, 47%-82%) 9(53%, 29%-77%) 0.5 
Growth Hormone 
Deficiency 
26(58%, 43%-72%) 18(64%, 47%-82%) 8(47%, 23%-71%) 0.4 
Adrenal Insufficiency 21(47%, 32%-61%) 17(61%, 43%-79%) 4(24%, 3%-44%) 0.03 
Sex steroid deficiency 17(38%, 24%-52%) 12(43%, 25%-61%) 5(29%, 8%-51%) 0.5 
Hypo/Hypergonadism 18(40%, 26%-54%) 13(46%, 28%-65%) 5(29%, 8%-51%) 0.4 
Diabetes Insipidus 17(38%, 24%-52%) 13(46%, 28%-65%) 4(24%, 3%-44%) 0.2 
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 CP and PLGG patients who received radiation treatment had a higher BMI at 5-
years after their diagnosis compared to those without (p = 0.04). In addition, patients who 
received radiation treatment were found to have a higher BMI at their most recent visit (p 
= 0.0055) compared to patients lacking radiation treatment (Table 6). 
 PLGG patients who received chemotherapy had significantly higher BMI at 6-
months post diagnosis (p=0.02) and at the most recent visit (p=0.02) compared to PLGG 
patients who did not receive treatment (Table 7). A comparison between PLGG and CP 
patients was not made since CP patients do not undergo chemotherapy.  
 
 
Table 5. Comparing the Impact of Surgery on PLGG and CP BMI  
 
 Surgery N Mean p-value* 
BMI at 6 months post 
diagnosis 
Yes 
 
33 3.5 0.7 
No 
 
2 4.0 
BMI at 5 years post diagnosis Yes 
 
37 3.8 0.9 
No 
 
3 4.0 
BMI at recent visit Yes 
 
41 4.6 0.6 
No 
 
4 5.0 
*two-sided p-values of Wilcoxon tests 
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Table 6. Comparing the Impact of Radiation Treatment on PLGG and CP BMI 
 Radiation N Mean p-value* 
BMI at 6 months post 
diagnosis 
Yes 
 
25 3.7 0.2 
No 
 
10 2.9 
BMI at 5 years post diagnosis Yes 
 
30 4.1 0.04  
No 
 
10 3.0 
BMI at recent visit Yes 
 
33 4.9 0.0055  
No 
 
12 3.9 
*two-sided p-values of Wilcoxon tests 
 
Table 7. Comparing Impact of Chemotherapy on PLGG BMI 
 Chemotherapy N Mean p-value* 
BMI at 6 months post 
diagnosis 
Yes 
 
28 3.8 0.02 
No 
 
7 2.3 
BMI at 5 years post diagnosis Yes 
 
34 4.0 0.1 
No 
 
6 2.8 
BMI at recent visit Yes 
 
38 4.8 0.02 
No 
 
7 3.7 
*two-sided p-values of Wilcoxon tests 
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 Descriptive statistical analysis in Figure 1 shows the cumulative radiation dose on 
each degree of obesity of PLGG patients at their most recent visit. ―Morbidly obese‖ 
patients were found to have a larger overall range, interquartile range, and associated 
with receiving a greater median cumulative radiation dose. This is in contrast with 
―Normal‖ and ―Obese‖ patients, who were found to have a lower median cumulative 
radiation dose and narrower range of dosage. 
 
 
Figure 1: Boxplot of cumulative radiation dose on each degree of obesity of PLGG 
patients at their most recent visit. 
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DISCUSSION 
 
 
  The purpose of this study was to compare hypothalamic damage in 
subjects diagnosed with pediatric hypothalamic low-grade glioma versus subjects 
diagnosed with childhood craniopharyngioma. It was hypothesized that CP patients will 
have a more prominent display of hypothalamic obesity; having a more rapid post 
diagnosis weight gain and a greater degree of obesity compared with PLGG patients. It 
was further hypothesized that there would be a greater number of endocrine dysfunctions 
that manifest in CP patients due to the greater proportion of patients undergoing invasive 
frontline procedures of surgery and radiation; shown to have a great impact on 
hypothalamic functionality. Hypothalamic PLGG patients receive less invasive 
procedures of chemotherapy and surveillance monitoring, opting for a more wait-and-see 
approach. However, this study suggests that there is no difference in the rate or 
magnitude of post diagnosis weight gain, indicating the manifestation of hypothalamic 
obesity in both CP and PLGG patients, and disproving our initial hypotheses. 
 We found that histological tumor types of craniopharyngioma or pediatric low-
grade glioma did not seem to have a relevant influence on the post diagnosis 
manifestation of hypothalamic obesity.  Rather, it is hypothalamic involvement, 
regardless of the histological tumor type itself, which seems to have a major impact on 
the development of obesity. There was not a statistically significant difference in BMI 
and BMI z-scores between CP and hypothalamic PLGG patients from the time of their 
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diagnosis until 6 months after diagnosis, 5 years after diagnosis, and their most recent 
visit, which in most cases was over 10 years after their initial diagnosis.  
 In addition, with the exception of ACTH, there was no difference in the 
proportion of patients who manifested endocrine dysfunctions. There were a statistically 
significant proportion of CP patients who presented with ACTH deficiency compared 
with PLGG patients. Previous reports attribute ACTH deficiency, and subsequently the 
rise in 11β-HSD1-derived corticosterone, as a mechanism for the cause of hypothalamic 
obesity in children, with an increase in adiposity, body mass, and insulin resistance. The 
fact that ACTH deficiency is less prevalent in PLGG patients appears to refute this claim 
and support the idea that endocrine deficiencies have less influence on the development 
of obesity. This is because PLGG patients still develop the same extent of obesity as CP 
patients, regardless of having normal pituitary ACTH secretion.  
 Gross total and subtotal resections, predominant frontline treatments of CP, were 
found to have little difference in BMI, when compared with the BMI of PLGG patients 
without surgery. This suggests the lack of influence invasive surgical procedures directly 
have on postoperative weight gain.  
 In contrast, the BMI in PLGG patients who received chemotherapy was higher 6 
months after diagnosis and at the most recent clinical visit compared with CP and PLGG 
patients who did not receive chemotherapy. This may be a risk factor for hypothalamic 
obesity in PLGG patients since 7 out of 17 PLGG patients (36 %) had some form of 
chemotherapy either alone or in conjunction with surgery and/or radiation, however 
further research needs to be conducted to confirm this claim.  
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 Patients who received radiation therapy had significantly higher BMI 5 years after 
initial tumor diagnosis and at their most recent clinical visit compared with those who 
didn’t receive radiation treatment. Furthermore, higher doses of radiation were associated 
with patients who tended to be morbidly obese at their most recent clinical visit. 
Radiation treatment has been utilized as a common modality of treatment for both PLGG 
and CP; confirms previous reports on the increased risk that radiation treatment has on 
long term obesity and the call for lower radiation dosage if possible.   
 The results of our study are limited due to retrospective analysis and some 
observations are speculative at this point without further research. Although we had a 
small sample size, we needed to discriminate the role of tumor histology versus tumor 
location on the sequelae of obesity. This study suggests a greater role that tumor location 
plays in the manifestation of hypothalamic damage, subsequently causing hypothalamic 
obesity. The degree of hypothalamic involvement of the tumor, rather than the histology 
of the tumor itself, seems to have a more relevant influence on hypothalamic damage and 
subsequent weight gain. 
 An in-depth comparison of post diagnostic weight gain in childhood 
craniopharyngioma and pediatric low-grade glioma patients has not been examined in the 
literature prior to this study. Retrospective analysis was necessary to understand the 
implications of tumor histology on the sequelae of hypothalamic obesity after tumor 
diagnosis. Further analysis should be conducted on tumor location and the extent of 
hypothalamic tumor involvement in an attempt to better understand the pathogenesis of 
hypothalamic obesity and improve the modalities of treatment in the future.  
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